Neboglamine

Neboglamine
Clinical data
Other names	Nebostinel; N-(4,4-Dimethylcyclohexyl)-L-α-glutamine
ATC code	None;
Identifiers
	IUPAC name (4S)-4-Amino-5-[(4,4-dimethylcyclohexyl)amino]-5-oxopentanoic acid;
CAS Number	163000-63-3;
PubChem CID	3074827;
ChemSpider	2333649;
UNII	12EA34U5B8;
CompTox Dashboard (EPA)	DTXSID2045787 ;
ECHA InfoCard	100.162.081
Chemical and physical data
Formula	C13H24N2O3
Molar mass	256.346 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1(CCC(CC1)NC(=O)C(CCC(=O)O)N)C;
	InChI InChI=1S/C13H24N2O3/c1-13(2)7-5-9(6-8-13)15-12(18)10(14)3-4-11(16)17/h9-10H,3-8,14H2,1-2H3,(H,15,18)(H,16,17)/t10-/m0/s1; Key:VCRGLZYPNNAVRP-JTQLQIEISA-N;

Neboglamine (INNTooltip International Nonproprietary Name) (developmental code names CR-2249, XY-2401), formerly known as nebostinel, is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence.^[1]^[2]^[3]^[4]^[5]^[6] It shows cognition- and memory-enhancing effects in animal models.^[7]^[8]^[9] As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse.^[10]